RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-0990-9458
Upstream and downstream revenue of upper gastrointestinal endoscopic ultrasound determined with an episode-of-care approach
Publikationsverlauf
submitted 05. März 2019
accepted after revision 08. Juli 2019
Publikationsdatum:
22. Oktober 2019 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00025476/201911/lookinside/thumbnails/1529_10-1055-a-0990-9458-1.jpg)
Abstract
Background and study aims Upper gastrointestinal endoscopic ultrasound (EUS) has clinical advantages that can lead to improved patient outcome. This study seeks to characterize and quantify the upstream and downstream healthcare utilizations and revenues.
Patients and methods A retrospective claims data analysis of upper gastrointestinal EUS procedures was conducted at a large health system. Types of care and total revenues associated with each episode of care were characterized by descriptive statistics. Comparisons were made between patients who had Medicare Advantage and commercial plans as well as those with and without cancer diagnoses during the downstream period.
Results A total of 436 cases were identified. The most frequent downstream healthcare utilizations consisted of radiology (31 %), pathology services (28 %), and high-revenue services including chemotherapy and inpatient admissions. The most common upstream utilizations included radiology (18 %) and lab services (22 %). Average total downstream revenue was $ 34 231 (95 %CI: $ 28 561 – $ 39 901) per case, and average total upstream revenue was $4373 (95 %CI: $3227 – $ 5519). Average total revenue per case did not differ significantly between Medicare Advantage and commercial plan members. However, patients who were diagnosed with cancer at or immediately following EUS (20 %) were associated with significantly higher total revenue compared to those without cancer diagnosis (P < 0.0001).
Conclusions This episode-of-care approach to quantifying the revenue impact of upper gastrointestinal EUS to the providers suggests there are substantial downstream as well as upstream revenues associated with upper gastrointestinal EUS procedures, driven by patients who are diagnosed with cancer by the EUS procedures and subsequently require oncologic care.
-
References
- 1 Fusaroli P, Caletti G. Endoscopic ultrasonography: current clinical role. Eur J Gastroenterol Hepatol 2005; 17: 293-301
- 2 Quirk DM, Rattner DW, Fernandez-del Castillo C. et al. The use of endoscopic ultrasonography to reduce the cost of treating ampullary tumors. Gastrointest Endosc 1997; 46: 334-337
- 3 Harewood GC, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of pancreatic head adenocarcinoma. Am J Gastroenterol 2001; 96: 2651-2656
- 4 Harewood GC, Wiersema MJ. A cost analysis of endoscopic ultrasound in the evaluation of esophageal cancer. Am J Gastroenterol 2002; 97: 452-458
- 5 Parada KS, Peng R, Erickson RA. et al. A resource utilization projection study of EUS. Gastrointest Endosc 2002; 55: 328-334
- 6 Aslanian HR, Ahmed AM, Jamidar PA. Is advanced endoscopy training worth it?. Clin Gastroenterol Hepatol 2015; 13: 1218-1220
- 7 Faigel DO. Economic realities of EUS in an academic practice. Gastrointest Endosc 2007; 65: 287-289
- 8 Harewood GC, Stemmer W, Roth J. et al. Resource-intensive endoscopy: revenue source or cash drain?. Gastrointest Endosc 2009; 70: 272-277
- 9 Barroso AO. Advanced endoscopy procedures in private practice: is the juice worth the squeeze?. Gastrointest Endosc 2011; 74: 913-915
- 10 IQVIA. Hospital Procedures and Diagnosis. https://www.iqvia.com/locations/united-states/medical-device-and-diagnostic-segment/hospital-procedures-and-diagnosis Accessed June 13, 2019
- 11 Hansen LG, Chang S. Health Research Data for the Real World: the MarketScan Databases. http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf [Accessed June 13, 2019]
- 12 Sodikoff JB, Garud SS, Keilin SA. et al. Health resource utilization and multidisciplinary impact of endoscopic ultrasonography in a tertiary referral medical center. Therap Adv Gastroenterol 2013; 6: 199-203
- 13 Atkinson M, Schmulewitz N. Downstream hospital charges generated from endoscopic ultrasound procedures are greater than those from colonoscopies. Clin Gastroenterol Hepatol 2009; 7: 862-867
- 14 Perri JL, Powell RJ, Goodney PP. et al. Disparity in Medicaid physician payments for vascular surgery. J Vasc Surg 2018; 68: 1946-1953
- 15 Maeng DD, Snyder SR, Baumgart C. et al. Medicaid managed care in an integrated health care delivery system: Lessons from Geisinger’s early experience. Popul Health Manag 2016; 19: 257-263
- 16 Jhala NC, Jhala DN, Chhieng DC. et al. Endoscopic ultrasound-guided fine-needle aspiration. A cytopathologist’s perspective. Am J Clin Pathol 2003; 120: 351-367
- 17 Eloubeidi MA, Jhala D, Chhieng DC. et al. Yield of endoscopic ultrasound-guided fine-needle aspiration biopsy in patients with suspected pancreatic carcinoma. Cancer 2003; 99: 285-292
- 18 Eloubeidi MA, Chen VK, Eltoum IA. et al. Endoscopic ultrasound-guided fine needle aspiration biopsy of patients with suspected pancreatic cancer: diagnostic accuracy and acute and 30-day complications. Am J Gastroenterol 2003; 98: 2663-2668
- 19 Wallace MB, Nietert PJ, Earle C. et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 2002; 74: 1026-1032